GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Qualigen Therapeutics Inc (FRA:7R90) » Definitions » General and Admin. Expense

Qualigen Therapeutics (FRA:7R90) General and Admin. Expense : €3.80 Mil (TTM As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Qualigen Therapeutics General and Admin. Expense?

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. Qualigen Therapeutics's General and Admin. Expense for the three months ended in Sep. 2024 was €1.03 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Sep. 2024 was €3.80 Mil.

Qualigen Therapeutics General and Admin. Expense Historical Data

The historical data trend for Qualigen Therapeutics's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qualigen Therapeutics General and Admin. Expense Chart

Qualigen Therapeutics Annual Data
Trend Mar20 Dec21 Dec22 Dec23
General and Admin. Expense
1.37 10.38 9.70 5.59

Qualigen Therapeutics Quarterly Data
Sep19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
General and Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.25 0.88 0.97 0.92 1.03

Qualigen Therapeutics General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €3.80 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Qualigen Therapeutics General and Admin. Expense Related Terms

Thank you for viewing the detailed overview of Qualigen Therapeutics's General and Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Qualigen Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Qualigen Therapeutics Inc (FRA:7R90) » Definitions » General and Admin. Expense
Comparable Companies
ZVSA THAR KANT OMGAQ PBM REVB QRON VCNX SCNI ADTX VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
QLGN:USA
Address
5857 Owens Avenue, Suite 300, Carlsbad, CA, USA, 92008
Website
https://www.qlgntx.com
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.

Qualigen Therapeutics Headlines

No Headlines